Quarterly report pursuant to Section 13 or 15(d)

Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses (Details)

v3.22.2.2
Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc $ 5,007 $ 5,203 $ 9,820 $ 6,639
Sales and Marketing Expenses [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 591 298 1,216 500
General and Administrative Expense [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 4,162 4,599 8,164 5,722
Research and Development Expense [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 254 306 440 417
Research and Development Expense [Member] | Lucid Diagnostics Inc [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 3,844 2,580 7,679 3,385
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Sales and Marketing Expenses [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 215 480
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 3,313 2,505 6,514 3,295
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 26 22 97 34
PAVmed Inc 2014 Equity Plan [Member] | Sales and Marketing Expenses [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 161 336
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc 77 145
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]        
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc $ 52 $ 53 $ 107 $ 56